Showing 7 of 7 recruiting trials for “Fibrolamellar hepatocellular carcinoma”
Peptide Vaccine for Fibrolamellar Hepatocellular Carcinoma Patients and Other Tumor Entities Carrying the Driver Fusion DNAJB1-PRKACA
Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma
👨⚕️ Michael V Ortiz, Pediatric Early Phase Clinical Trial Network📍 20 sites📅 Started Jun 2025View details ↗
DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)
👨⚕️ Marina Baretti, MD, SKCCC • Johns Hopkins Medical Institution📍 1 site📅 Started Feb 2024View details ↗
FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined with Immune Checkpoint Inhibition
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
👨⚕️ Jessica Gartrell, MD, St. Jude Children's Research Hospital📍 2 sites📅 Started Nov 2022View details ↗
Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →